再发性心肌梗死二级预防中药物治疗的研究进展  

Research progress of pharmacological therapy in secondary prevention of recurrent myocardial infarction

作　　者：潘刚[1] 张卫泽[1] 支延春 

机构地区：[1]兰州军区兰州总医院心内科,甘肃兰州730050 [2]兰州大学第二医院心内科,甘肃兰州730030

出　　处：《心脏杂志》2015年第6期740-742,共3页Chinese Heart Journal

基　　金：全军医药卫生科研基金项目资助(CLZ2J014)

摘　　要：近年来对再发性心肌梗死(RMI)二级预防的研究不断增多,本文将以经典的临床指南为基础,汇总近年来二级预防药物的相关理论研究与临床观察的新成果,并对其临床意义和不足之处试做评述,以此希望对临床实践和科学研究有所帮助。In recent years, more and more research has been conducted in the secondary prevention of recurrent myocardial infarction. This article, based on classic guidelines, will review some new theoretical findings and clinical observations from the perspective of pharmacological therapy and provide some preliminary comments on their clinical significance as well as inadequacies.

关 键 词：心肌梗死 再发性 二级预防 药物 

分 类 号：R542.22[医药卫生—心血管疾病]